 |
13 Companies | 15 Products |
|
|
15 Products | |
46 Diseases | |
8 Trials |  |
488 News |  |
| «12...567891011121314151617 |
- | Journal: Prognostic value of tumor infiltration immune cells in pancreatic cancer (Pubmed Central) - Apr 7, 2019
Tumour-infiltrating Treg, MDSC level and pTNM stage are independent prognostic factors for patients with pancreatic cancer. Treg and MDSC depletion therapy can significantly retard tumour growth and increase the level of tumour-infiltrating CD8(+) T-cells in the C57BL/6 mouse model of subcutaneous tumours.
- | Journal: CLT030, a leukemic stem cell-targeting CLL1 antibody-drug conjugate for treatment of acute myeloid leukemia. (Pubmed Central) - Apr 5, 2019
CLL1-ADC demonstrated a reduced effect on differentiation of healthy normal human CD34 cells to various lineages as observed in an in vitro colony formation assay and in an in vivo xenotransplantation model as compared with CD33-ADC. These results demonstrate that CLL1-ADC could be an effective ADC therapeutic for the treatment of AML.
- | Journal: Flow cytometry identification of nonhemopoietic neoplasms during routine immunophenotyping. (Pubmed Central) - Apr 5, 2019
These results demonstrate that CLL1-ADC could be an effective ADC therapeutic for the treatment of AML. The current results show that when CD45- cells with altered scatter parameters were detected, cytometrists involved in leukaemia/lymphoma diagnosis may require further FC investigations to rapidly identify NHNs in different specimens, thus reducing the time of the immunohistochemical diagnostic workup to reach a final diagnosis.
- | Campath (alemtuzumab) / Sanofi
Journal, CAR T-Cell Therapy: Compound CAR T-cells as a double-pronged approach for treating acute myeloid leukemia. (Pubmed Central) - Apr 3, 2019
We also designed an alemtuzumab safety-switch that allowed for rapid cCAR therapy termination in vivo. These findings indicate that targeting both CD123 and CD33 on AML cells may be an effective strategy for eliminating both AML bulk disease and LSCs, and potentially prevent relapse due to antigen escape or LSC persistence.
- | Journal: Revising flow cytometric mini-panel for diagnosing low-grade myelodysplastic syndromes: Introducing a parameter quantifying CD33 expression on CD34+ cells. (Pubmed Central) - Mar 27, 2019
Based on the results, we constructed a new scoring system, which showed approximately 50% sensitivity and more than 95% specificity in diagnosing low-grade MDS. Our revised mini-panel is suitable for screening samples suspected for MDS and provides a basis for further improvement in diagnostic FCM protocols for MDS.
- | CRISPR-Cas9 gene editing therapeutic / CRISPR Therap
Review, Journal: Genetics of Alzheimer's Disease. (Pubmed Central) - Mar 26, 2019
CRISPR-CAS9 can directly link genetic knowledge to future treatment. Single-cell RNA sequencing are providing useful information on cell biology and pathogenesis of diverse diseases.
- | Biomarker, Clinical, Journal: CD33 splicing SNP regulates expression levels of CD33 in normal regenerating monocytes in AML patients. (Pubmed Central) - Mar 21, 2019
Single-cell RNA sequencing are providing useful information on cell biology and pathogenesis of diverse diseases. No abstract available
- | Journal, CAR T-Cell Therapy, IO biomarker: Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia. (Pubmed Central) - Mar 6, 2019
CD33-deficient cells were impervious to CD33-targeting CAR T cells, allowing for efficient elimination of leukemia without myelotoxicity. These studies illuminate a novel approach to antigen-specific immunotherapy by genetically engineering the host to avoid on-target, off-tumor toxicity.
- | Journal: Induction chemotherapy in acute myeloid leukaemia: origins and emerging directions. (Pubmed Central) - Jan 13, 2019
However, its success is limited in a subset of patients by toxicity, failure to achieve remission and potential for subsequent relapse. Novel agents such as mutant fms like tyrosine kinase 3 inhibitors, mutant isocitrate dehydrogenase inhibitors, CD33-antibody drug conjugates and liposomal formulations have demonstrated significant potential as modifications to traditional induction chemotherapy.
- | Mylotarg (gemtuzumab ozogamicin) / UCB, PDL, Pfizer
Biomarker, Review, Journal: The return of gemtuzumab ozogamicin: a humanized anti-CD33 monoclonal antibody-drug conjugate for the treatment of newly diagnosed acute myeloid leukemia. (Pubmed Central) - Dec 15, 2018
Herein, we also review the clinical efficacy of GO in the frontline treatment of acute promyelocytic leukemia, which is based on either initial patient high-risk disease or potential co-morbidities that preclude the use of arsenic trioxide (ATO). Finally, we assess the current evidence for biomarkers aside from initial cytogenetics that may predict a favorable response to GO.
- | cisplatin / Generic mfg., gemcitabine / Generic mfg.
Clinical, Review, Journal, Myeloid-derived suppressor cells: Myeloid-derived suppressors cells (MDSC) correlate with clinicopathologic factors and pathologic complete response (pCR) in patients with urothelial carcinoma (UC) undergoing cystectomy. (Pubmed Central) - Nov 7, 2018
Blood and tissue MDSC levels correlate with several clinicopathologic factors and may predict for pCR. Future studies are needed to highlight the role of MDSC in predicting long-term outcomes and to determine the clinical implications of these findings.
- | Venclexta (venetoclax) / Roche, AbbVie, Reblozyl (luspatercept-aamt) / Acceleron, BMS
Journal, IO biomarker: Recent advances in the cellular and molecular understanding of myelodysplastic syndromes: implications for new therapeutic approaches. (Pubmed Central) - Sep 28, 2018
Agents in clinical trials for subsets of MDS include luspatercept, antibodies targeting CD33, isocitrate dehydrogenase inhibitors, deacetylase inhibitors, venetoclax, and immunotherapies designed to overcome immune checkpoint inhibition. These biologically based therapeutics, as well as the encouraging precedent of 7 new approvals by the US Food and Drug Administration in 2017 for the treatment of acute leukemia, offer the prospect that 10 more years will not elapse before another new therapy is approved for MDS.